Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171029 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL6645277 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL10864606 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL13995941 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL13995928 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL4051277 | 0.83 | CYP1A2 (0.58) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL21810992 | 0.83 | CYP1A2 (0.58) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL104748 | 0.82 | CYP1A2 (0.62) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL9345944 | 0.82 | CYP1A2 (0.62) | CYP1A2CYP2D6ALDH1A1PKMKMT2A | |
| SCHEMBL19954195 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP2D6ALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | CYP1A2 4431/4885CYP2D6 1534/4885ALDH1A1 3935/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CYP1A2 4191/4885CYP2D6 1822/4885ALDH1A1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.